New lupus drug Benlysta passes second clinical trial
Wednesday November 4, 2009
The LA Times is reporting that Benlysta, a new drug designed to treat lupus, has passed an important second clinical trial. The drug's maker, Human Genome Sciences, plans to apply for FDA approval next year. If approved, Benlysta will be the first new treatment for lupus in 50 years.
In the clinical trial, 43.2% of patients who took Benlysta in addition to their usual treatment saw their symptoms reduced, compared to 33.8% of people on a placebo.